An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film

Contraception Clinical Trial

Official title:

An Exploratory Phase 1 Mechanism-of-action Study of ZB-06, a Vaginal Film Containing HC4-N, an Anti-sperm Monoclonal Antibody.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04731818
• Other study ID #: ZB-06-01
• Status: Completed
• Phase: Early Phase 1
• Start date: January 27, 2021
• Est. completion date: April 27, 2022

Study information

• Verified date: March 2023
• Source: KBio Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an early Phase 1 study to establish proof-of-concept by determining whether an intravaginal film containing a human contraceptive antibody (ZB-06) shows promise to provide contraceptive efficacy using the post-coital test, a surrogate measure of efficacy. The study will also evaluate the safety and pharmacokinetics of ZB-06.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 27, 2022
• Est. primary completion date: February 24, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age 18 - 50 years, inclusive

• General good health, by volunteer history and per investigator judgment

• History of regular menstrual cycles of 21 - 35 days (inclusive), by volunteer report

• History of a normal PAP smear or ASCUS with negative HPV testing within the previous 12 months

• Willing to abstain from intercourse and use of vaginal medications, lubricants, and other products as required in the protocol

• Willing to use non-spermicidal, lubricated condoms for any vaginal intercourse from the first day of each menstrual cycle until 72 hours before expected midcycle

• In a mutually monogamous relationship with a male partner who:

• Is at least 18 years old

• Has no known risk for sexually transmitted infections (STIs)

• Is willing and able to comply with protocol requirements including sexual activity/ abstinence and condom use requirements

• Can engage in vaginal intercourse with the participant, with and without condoms, as specified in protocol

• Protected from pregnancy by female surgical sterilization

• Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection

• Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol

Exclusion Criteria:

• History of hysterectomy

• Surgical sterility or known history of infertility in male partner

• Sterility or known history of sperm dysfunction in male partner

• Currently pregnant by urine pregnancy test at the enrollment visit, or within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome

• Current use of any hormonal contraceptive or a copper or hormonal IUD, or use of Depo-Provera in the last 120 days

• Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study

• Significant gynecological abnormalities (including abnormal vaginal bleeding, excessive vaginal discharge, or vulvar/vaginal pain or irritation)

• Current UTI, vaginal candidiasis, or symptomatic bacterial vaginosis

• History of sensitivity/allergy to ZB-06 film components, for either the volunteer or her male partner

• In the last three months, either the volunteer or her male partner diagnosed with or treated for any STI or pelvic inflammatory disease, or either partner with known risk factors for sexually transmitted infections. Note: Women with a history of genital herpes or condylomata who have been asymptomatic for at least six months may be considered for eligibility

• Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, or HIV at the screening visit

• Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for an STI

• Known current drug or alcohol abuse which could impact study compliance

• Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study

• History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days

• Abnormal finding on laboratory or physical examination or a social or medical condition in either the volunteer or her male partner which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data

Related Conditions & MeSH terms

• Contraception

Intervention

Biological:
• ZB-06
ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.

Locations

Country	Name	City	State
United States	Eastern Virginia Medical School	Norfolk	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
KBio Inc	Eastern Virginia Medical School

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetic Antibodies	Concentration of ZB-06 human contraceptive antibody in vaginal fluid, endocervical mucus, and serum.	Baseline, 2-3 hours & 24 hours & 1-month post-intercourse, with and without product use.
Other	Agglutination Titers	Sperm agglutination titer of ZB-06 human contraceptive antibody in vaginal fluid, endocervical mucus, and serum by endpoint dilution.	Baseline, 2-3 hours & 24 hours & 1-month post-intercourse, with and without product use.
Primary	Surrogate Contraceptive Efficacy	Number of progressively motile sperm in aspirated endocervical mucus when using ZB-06 prior to intercourse.	2-3 hours after sexual intercourse.
Secondary	Adverse Events	Incidence of Grade 2 or Greater Adverse Events during product use versus during baseline observation.	Baseline through study exit encompassing a minimum of three menstrual cycles of 21-35 days.